Palivizumab prophylaxis in 'late preterm' newborns

Area of Science:

• Neonatology
• Pediatric Infectious Diseases
• Public Health

Background:

• Preterm birth rates, particularly for late preterm infants (34-36 weeks gestational age), have risen over 20% in recent decades.
• Late preterm infants exhibit immature respiratory and immune systems, increasing susceptibility to pathogens like respiratory syncytial virus (RSV).
• Serious RSV illness risk is comparable between late preterm and very preterm infants (≤32 weeks gestational age), and higher than in full-term infants.

Purpose of the Study:

• To evaluate the effectiveness and cost-effectiveness of palivizumab for preventing RSV in late preterm infants.
• To discuss the American Academy of Pediatrics (AAP) recommendations for palivizumab administration in specific late preterm populations.
• To highlight the need for country-specific risk assessment tools for RSV prevention strategies.

Main Methods:

• Review of existing literature on preterm birth rates, RSV susceptibility, and palivizumab efficacy.
• Analysis of AAP guidelines for palivizumab use in late preterm infants.
• Discussion of the development and rationale for a European risk scoring tool for RSV epidemics.

Main Results:

• Palivizumab is effective in reducing RSV-related hospitalizations in preterm neonates.
• AAP suggests targeted palivizumab administration for infants born between 32 0/7 and 34 6/7 weeks gestational age with risk factors during RSV season.
• Environmental and demographic factors necessitate localized risk assessment for RSV epidemic severity.

Conclusions:

• Palivizumab is a key intervention for preventing serious RSV illness in vulnerable preterm infants.
• Tailoring palivizumab guidelines based on national risk factors and epidemic patterns is crucial for maximizing cost-effectiveness.
• Individualized risk assessment and country-specific recommendations are essential for optimal RSV prevention in late preterm infants.